Potential role of fluoroquinolones in pediatric infections.

S. M. Douidar, W. R. Snodgrass

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The fluoroquinolones are new, broad-spectrum, bactericidal antimicrobial agents structurally related to nalidixic acid. They are well absorbed after oral administration, with serum and tissue levels generally in excess of the minimal inhibitory concentrations for susceptible organisms. Their spectrum of activity includes serious pediatric pathogens such as Haemophilus influenzae, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. The potential uses of fluoroquinolones in pediatric diseases include acute and chronic pulmonary infections in children with cystic fibrosis, methicillin-resistant staphylococcal infections, meningitis with resistant bacteria, and prophylaxis in leukemic and immunocompromised children. The toxicity of some quinolone derivatives that involve developing cartilage in sensitive animal species has to be studied further. Clinical trials of fluoroquinolones from Europe and the United States in children show no cartilage or joint toxicity. For the time being and until more clinical experience with fluoroquinolones in children is obtained, their use should be limited to specific cases of therapeutic failure or multiple resistance to other antibiotics.

Original languageEnglish (US)
Pages (from-to)878-889
Number of pages12
JournalReviews of Infectious Diseases
Volume11
Issue number6
StatePublished - Nov 1989

Fingerprint

Fluoroquinolones
Pediatrics
Infection
Cartilage
Staphylococcal Infections
Nalidixic Acid
Methicillin Resistance
Quinolones
Haemophilus influenzae
Acute Disease
Methicillin-Resistant Staphylococcus aureus
Anti-Infective Agents
Meningitis
Cystic Fibrosis
Pseudomonas aeruginosa
Oral Administration
Chronic Disease
Joints
Clinical Trials
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Douidar, S. M., & Snodgrass, W. R. (1989). Potential role of fluoroquinolones in pediatric infections. Reviews of Infectious Diseases, 11(6), 878-889.

Potential role of fluoroquinolones in pediatric infections. / Douidar, S. M.; Snodgrass, W. R.

In: Reviews of Infectious Diseases, Vol. 11, No. 6, 11.1989, p. 878-889.

Research output: Contribution to journalArticle

Douidar, SM & Snodgrass, WR 1989, 'Potential role of fluoroquinolones in pediatric infections.', Reviews of Infectious Diseases, vol. 11, no. 6, pp. 878-889.
Douidar, S. M. ; Snodgrass, W. R. / Potential role of fluoroquinolones in pediatric infections. In: Reviews of Infectious Diseases. 1989 ; Vol. 11, No. 6. pp. 878-889.
@article{7c178d4dc6474847b7f4b1aec96b6b3f,
title = "Potential role of fluoroquinolones in pediatric infections.",
abstract = "The fluoroquinolones are new, broad-spectrum, bactericidal antimicrobial agents structurally related to nalidixic acid. They are well absorbed after oral administration, with serum and tissue levels generally in excess of the minimal inhibitory concentrations for susceptible organisms. Their spectrum of activity includes serious pediatric pathogens such as Haemophilus influenzae, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. The potential uses of fluoroquinolones in pediatric diseases include acute and chronic pulmonary infections in children with cystic fibrosis, methicillin-resistant staphylococcal infections, meningitis with resistant bacteria, and prophylaxis in leukemic and immunocompromised children. The toxicity of some quinolone derivatives that involve developing cartilage in sensitive animal species has to be studied further. Clinical trials of fluoroquinolones from Europe and the United States in children show no cartilage or joint toxicity. For the time being and until more clinical experience with fluoroquinolones in children is obtained, their use should be limited to specific cases of therapeutic failure or multiple resistance to other antibiotics.",
author = "Douidar, {S. M.} and Snodgrass, {W. R.}",
year = "1989",
month = "11",
language = "English (US)",
volume = "11",
pages = "878--889",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Potential role of fluoroquinolones in pediatric infections.

AU - Douidar, S. M.

AU - Snodgrass, W. R.

PY - 1989/11

Y1 - 1989/11

N2 - The fluoroquinolones are new, broad-spectrum, bactericidal antimicrobial agents structurally related to nalidixic acid. They are well absorbed after oral administration, with serum and tissue levels generally in excess of the minimal inhibitory concentrations for susceptible organisms. Their spectrum of activity includes serious pediatric pathogens such as Haemophilus influenzae, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. The potential uses of fluoroquinolones in pediatric diseases include acute and chronic pulmonary infections in children with cystic fibrosis, methicillin-resistant staphylococcal infections, meningitis with resistant bacteria, and prophylaxis in leukemic and immunocompromised children. The toxicity of some quinolone derivatives that involve developing cartilage in sensitive animal species has to be studied further. Clinical trials of fluoroquinolones from Europe and the United States in children show no cartilage or joint toxicity. For the time being and until more clinical experience with fluoroquinolones in children is obtained, their use should be limited to specific cases of therapeutic failure or multiple resistance to other antibiotics.

AB - The fluoroquinolones are new, broad-spectrum, bactericidal antimicrobial agents structurally related to nalidixic acid. They are well absorbed after oral administration, with serum and tissue levels generally in excess of the minimal inhibitory concentrations for susceptible organisms. Their spectrum of activity includes serious pediatric pathogens such as Haemophilus influenzae, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. The potential uses of fluoroquinolones in pediatric diseases include acute and chronic pulmonary infections in children with cystic fibrosis, methicillin-resistant staphylococcal infections, meningitis with resistant bacteria, and prophylaxis in leukemic and immunocompromised children. The toxicity of some quinolone derivatives that involve developing cartilage in sensitive animal species has to be studied further. Clinical trials of fluoroquinolones from Europe and the United States in children show no cartilage or joint toxicity. For the time being and until more clinical experience with fluoroquinolones in children is obtained, their use should be limited to specific cases of therapeutic failure or multiple resistance to other antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=0024763252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024763252&partnerID=8YFLogxK

M3 - Article

C2 - 2513628

AN - SCOPUS:0024763252

VL - 11

SP - 878

EP - 889

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -